Treatment with Growth Hormone and Luteinizing Hormone Releasing Hormone Analog Improves Final Adult Height in Children with Congenital Adrenal Hyperplasia
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Final adult height is often compromised in children with congenital adrenal hyperplasia (CAH). This study examines the impact of GH and LHRH analog (LHRHa) on final adult height in patients with CAH due to 21-hydroxylase deficiency. Fourteen patients with CAH (eight males, six females) predicted to be more than 1.0 sd below their midparental target height received GH and LHRHa until final height. Each patient was matched at the start of GH therapy to a CAH patient treated only with glucocorticoids according to type of CAH, sex, and chronological age. Mean age, bone age, height, height prediction, and target height were the same in both groups at the beginning of GH therapy. Mean duration of GH treatment was 4.4 +/- 1.5 yr. Mean duration of LHRHa therapy was 4.2 +/- 2.0 yr. In the treatment group, final height sd score of -0.4 + 0.8 was significantly greater than both the initial prediction of -1.5 +/- 0.9 (P < 0.0001) and the final height sd score of the untreated group of -1.4 +/- 1.1 (P = 0.01). Our results indicate that the combination of GH and LHRHa improves final adult height in patients with CAH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Fourteen patients treated with growth hormone and GnRH plus conventional therapy for ;4 years had improved adult height (+1.1 SDS) (323) compared with historical controls with CAH treated with conventional therapy alone (SDS of 20.4 vs 21.4,P = 0.01).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [323]
Citations
Cites
RADIOGRAPHIC ATLAS OF SKELETAL DEVELOPMENT OF THE HAND AND WRIST
GREULICH, W. W., & PYLE, S. I. (1959) · The American Journal Of The Medical Sciences · doi:10.1097/00000441-195909000-00030 · Cited by 5,585
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency*
White, P. C., & Speiser, P. W. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.3.0398 · Cited by 1,432
Bayley, N., & Pinneau, S. R. (1952) · The Journal of Pediatrics · doi:10.1016/s0022-3476(52)80205-7 · Cited by 1,196 · cited 2×
“Predicted adult height was calculated using BA and height according to the Bayley-Pinneau method (38).”
MethodClinical longitudinal standards for height and height velocity for North American children
Tanner, J. M., & Davies, P. S. W. (1985) · The Journal of Pediatrics · doi:10.1016/s0022-3476(85)80501-1 · Cited by 1,092 · cited 2×
“However, the groups were still similar with regards to onset of puberty in that the majority of subjects (10 of 14 in each group) had early onset of puberty (before age 10 in girls and age 11 in boys) (41).”
BackgroundStandards for Children's Height at Ages 2-9 Years Allowing for Height of Parents
Tanner, J. M., Goldstein, H., & Whitehouse, R. H. (1970) · Archives of Disease in Childhood · doi:10.1136/adc.45.244.755 · Cited by 812
Tanner, J. M., Whitehouse, R. H., Marshall, W. A., & Carter, B. S. (1975) · Archives of Disease in Childhood · doi:10.1136/adc.50.1.14 · Cited by 348
GROWTH SUPPRESSION BY GLUCOCORTICOID THERAPY
Allen, D. B. (1996) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70348-0 · Cited by 227 · cited 1×
“activity, as well as bone formation and collagen formation, processes essential for normal growth (28).”
BackgroundThe suppression of androgen secretion by cortisone in a case of congenital adrenal hyperplasia.
Wilkins, L., Ra, L., Klein, R., & ROSEMBERG, E. (1950) · PubMed · Cited by 218
Long Term Outcome in Adult Males with Classic Congenital Adrenal Hyperplasia1
Cabrera, M. S., Vogiatzi, M. G., & New, M. I. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7668 · Cited by 204
Self-citationPESCOVITZ, O. H., HENCH, K. D., BARNES, K. M., LORIAUX, D. L., & CUTLER, G. B. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-3-474 · Cited by 198
Glucocorticoid Effects on Somatomedins and Somatomedin Inhibitors*
UNTERMAN, L. S., & PHILLIPS, S. L. S. (1985) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-61-4-618 · Cited by 189
Klingensmith, G. J., Garcia, S. C., Jones, H. W., Migeon, C. J., & Blizzard, R. M. (1977) · The Journal of Pediatrics · doi:10.1016/s0022-3476(77)80581-7 · Cited by 163 · cited 6×
“3320 J Clin Endocrinol Metab, June 2005, 90(6):3318–3325 Lin-Su et al.”
BackgroundInfluentialJääskeläinen, J., & Voutilainen, R. (1997) · Pediatric Research · doi:10.1203/00006450-199701000-00005 · Cited by 160
Treatment of Glucocorticoid-Induced Growth Suppression with Growth Hormone
Allen, D. B., Julius, J. R., Breen, T. J., & Attie, K. M. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.5036 · Cited by 153
Merke, D. P., Bornstein, S. R., Avila, N. A., & Chrousos, G. P. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-4-200202190-00012 · Cited by 147
PESCOVITZ, O. H., COMITE, F., CASSORLA, F., DWYER, A. J., POTH, M. A., SPERLING, M. A., HENCH, K., McNEMAR, A., SKERDA, M., LORIAUX, D. L., et al. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-58-5-857 · Cited by 144 · cited 1×
“Second, central precocious puberty often develops in patients with CAH due to androgen activation of the hypothalamic-pituitary-gonadal axis, thus exacerbating premature epiphyseal fusion (29, 30).”
BackgroundGirgis, R., & Winter, J. S. D. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4320 · Cited by 139
Longer term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience
Premawardhana, L. D. K. E., Hughes, I. A., Read, G. F., & Scanlon, M. F. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.1360962.x · Cited by 135
Rivkees, S. A., & Crawford, J. D. (2000) · PEDIATRICS · doi:10.1542/peds.106.4.767 · Cited by 130
(1988) · PubMed · Cited by 110
Self-citationBalsamo, A., Cicognani, A., Baldazzi, L., Barbaro, M., Baronio, F., Gennari, M., Bal, M., Cassio, A., Kontaxaki, K., & Cacciari, E. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030123 · Cited by 102
Pinto, G., Tardy, V., Trivin, C., Thalassinos, C., Lortat-Jacob, S., Nihoul-Fékété, C., Morel, Y., & Brauner, R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021433 · Cited by 101
Manoli, I., Kanaka‐Gantenbein, C., Voutetakis, A., Maniati‐Christidi, M., & Dacou‐Voutetakis, C. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01645.x · Cited by 100
Quintos, J. B. Q., Vogiatzi, M. G., Harbison, M. D., & New, M. I. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.4.7412 · Cited by 96 · cited 2×
“improvement in growth velocity and predicted height (16),”
BackgroundSelf-citationInhibition by Prednisone of Growth Hormone (GH) Response to GH-Releasing Hormone in Normal Men
KAUFMANN, S., JONES, K. L., WEHRENBERG, W. B., & CULLER, F. L. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-6-1258 · Cited by 87
Touati, G., Prieur, A. M., Ruiz, J. C., Noel, M., & Czernichow, P. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.2.4569 · Cited by 85
The effect of treatment of final height in classical congenital adrenal hyperplasia (CAH)
DiMartino-Nardi, J., Stoner, E., O'Connell, A., & New, M. I. (1986) · Acta Endocrinologica · doi:10.1530/acta.0.112s305 · Cited by 77
Self-citationGrowth and body proportions in congenital adrenal hyperplasia.
Young, M. C., Ribeiro, J., & Hughes, I. A. (1989) · Archives of Disease in Childhood · doi:10.1136/adc.64.11.1554 · Cited by 55
Yu, A., & Grant, D. (1995) · Acta Paediatrica · doi:10.1111/j.1651-2227.1995.tb13789.x · Cited by 52 · cited 3×
“Likewise, Yu and Grant (18) found the mean adult height sd scores (SDSs) of women treated for CAH in childhood to be 1.2 sd below that expected for parental heights.”
BackgroundInfluentialDACOU‐VOUTETAKIS, C., & KARIDIS, N. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb43873.x · Cited by 49 · cited 1×
“Second, central precocious puberty often develops in patients with CAH due to androgen activation of the hypothalamic-pituitary-gonadal axis, thus exacerbating premature epiphyseal fusion (29, 30).”
BackgroundAdrenal 21‐hydroxylase deficiency in childhood: 25 years' experience
LIM, Y. J., BATCH, J. A., & WARNE, G. L. (1995) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.1995.tb00790.x · Cited by 43
Kohn, B., Julius, J. R., & Blethen, S. L. (1999) · PEDIATRICS · doi:10.1542/peds.104.s5.1014 · Cited by 39 · cited 2×
“GH has also been used in conjunction with LHRHa to improve final height in children with central precocious puberty (35, 36).”
Evaluation of Young Women with Congenital Adrenal Hyperplasia: A Pilot Study
van der Kamp, H. J., Slijper, F. M. E., Brandenburg, H., Keizer-Schrama, D. M., Drop, S., & Molenaar, J. (1992) · Hormone Research · doi:10.1159/000182400 · Cited by 37
Combined Therapy with GnRH Analog Plus Growth Hormone in Central Precocious Puberty
Pucarelli, I., Segni, M., Ortore, M., Moretti, A., Iannaccone, R., & Pasquino, A. M. (2000) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2000.13.s1.811 · Cited by 34 · cited 2×
“GH has also been used in conjunction with LHRHa to improve final height in children with central precocious puberty (35, 36).”
BackgroundMethodPenny, R., Olambiwonnu, N. O., & Frasier, S. D. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-36-5-920 · Cited by 32
[Final height in 69 patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency].
David, M., Sempe, M., Blanc, M., Nicolino, M. P., Forest, M., & Morel, Y. (1994) · PubMed · Cited by 32
Factors Determining Final Height in Congenital Adrenal Hyperplasia
New, M. I. (2001) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2001-s204 · Cited by 30
Self-citationHauffa, B., Winter, A., & Stolecke, H. (1997) · Klinische Pädiatrie · doi:10.1055/s-2008-1043931 · Cited by 27
Brunelli, V., Russo, G., Bertelloni, S., Gargantini, L., Balducci, R., Chiesa, L., Livieri, C., De Sanctis, C., Einaudi, S., Virdis, R., et al. (2003) · PubMed · Cited by 26
Unresolved problems in the treatment of congenital adrenal hyperplasia.
Tanae, A., & Hibi, I. (1988) · PubMed · Cited by 13
Cited by
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
“When doses exceed 20 mg/m · d in infants and 15– 17 mg/m · d in adolescents, there is loss of height SD score (SDS) and shorter adult height SDS (123,124,125,126,127).”
InfluentialSpeiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Consensus Statement on the Use of Gonadotropin-Releasing Hormone Analogs in Children
Carel, J.-C., Eugster, E. A., Rogol, A., Ghizzoni, L., Palmert, M. R., & on behalf of the members of the ESPE-LWPES GnRH Analogs Consensus Conference Group (2009) · Pediatrics · doi:10.1542/peds.2008-1783 · Cited by 817
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Nonclassical 21-Hydroxylase Deficiency
New, M. I. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1645 · Cited by 315
Self-citation
Metadata
- Authors
- Lin-Su, K., Vogiatzi, M. G., Marshall, I., Harbison, M. D., Macapagal, M. C., Betensky, B., Tansil, S., & New, M. I.
- Affiliations
- Cornell University (US)
- Rutgers, The State University of New Jersey (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- New, Maria I.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-06
- Volume
- 90
- Issue
- 6
- Pages
- 3318-3325
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2046147708
- Cited by
- 111
- References
- 40
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 2 · 2023: 4 · 2021: 3 · 2020: 2 · 2019: 5 · 2018: 2 · 2016: 3 · 2015: 8 · 2014: 5 · 2013: 9 · 2012: 1
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Center for Research Resources (RR06020)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD 00072)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- congenital adrenal hyperplasia, 21-hydroxylase deficiency, growth hormone therapy, luteinizing hormone-releasing hormone analogue, adult height, short stature, glucocorticoid therapy, height prediction
- MeSH terms
- Adolescent, Adrenal Hyperplasia, Congenital, Adult, Body Height, Child, Female, Growth, Humans, Gonadotropin-Releasing Hormone, Male, Treatment Outcome, Human Growth Hormone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.